Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 5/20 | 0.42 |
| ▸ | CDK2 | P24941 | 5/20 | 0.42 |
| ▸ | CDK5 | Q00535 | 5/20 | 0.42 |
| ▸ | LCK | P06239 | 4/20 | 0.39 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.38 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.38 |
| ▸ | FFAR2 | O15552 | 2/20 | 0.37 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.35 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.35 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.35 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.35 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.35 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19003795 | 0.85 | CYP3A4 (0.43) | CCNE1CDK2CDK5LCKP2RY2 | |
| SCHEMBL10124744 | 0.84 | LCK (0.35) | CCNE1CDK2CDK5LCKP2RY2 | |
| SCHEMBL1691012 | 0.84 | LCK (0.35) | CCNE1CDK2CDK5LCKP2RY2 | |
| SCHEMBL1926160 | 0.84 | LCK (0.35) | CCNE1CDK2CDK5LCKP2RY2 | |
| SCHEMBL10125058 | 0.84 | LCK (0.35) | CCNE1CDK2CDK5LCKP2RY2 | |
| SCHEMBL16681690 | 0.84 | LCK (0.35) | CCNE1CDK2CDK5LCKP2RY2 | |
| SCHEMBL1691316 | 0.84 | LCK (0.35) | CCNE1CDK2CDK5LCKP2RY2 | |
| SCHEMBL21395245 | 0.83 | CCNE1 (0.41) | CCNE1CDK2CDK5LCKP2RY2 | |
| SCHEMBL29358389 | 0.83 | CCNE1 (0.41) | CCNE1CDK2CDK5LCKP2RY2 | |
| SCHEMBL19003727 | 0.81 | OGA (0.44) | CCNE1CDK2CDK5LCKP2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170174675-A9 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | VERTEX PHARMACEUTICALS INCORPORATED | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174675-A9 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | CFTR, SCNN1G, SCNN1B | CCNE1 4809/4885CDK2 4554/4885CDK5 4475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.